Polypeptides comprising inteins for engineering outer vesicles
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- EVOX THERAPEUTICS LTD
- Filing Date
- 2024-09-27
- Publication Date
- 2026-07-10
AI Technical Summary
In the prior art, premature cleavage of the in-cell peptide between the EV polypeptide or EV localization site and the biotherapy agent leads to reduced cargo loading efficiency and may cause cellular stress and reduced EV yield, making it difficult to purify pure EV products.
We developed peptides containing ΔI-CM introns and novel exotropic peptide sequences, designed for intron-mediated cleavage with reduced expression in the cytoplasm, and controlled cargo release through pH and temperature-sensitive cleavage to improve EV loading efficiency and bioactivity.
It enables more efficient cargo loading and unloading in EVs, reduces the risk of premature cutting, improves the biocompatibility and yield of EVs, and provides a flexible EV loading platform.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3